Totality of Evidence from BeAT-HF Study Shows CVRx's Barostim Provides Long-term Benefits for Patients with Heart Failure MINNEAPOLIS

Totality of Evidence from BeAT-HF Study Shows

CVRx's Barostim Provides Long-term Benefits for Patients with Heart Failure

MINNEAPOLIS, Mar. 21, 2023 -

CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing

and commercializing Barostim , an innovative extravascular implantable neuromodulation device for patients with cardiovascular

diseases, announced detailed preliminary results of the post-market phase of the BeAT-HF trial at the second annual Technology and Heart

Failure (HF) Therapeutics (THT) conference on Tuesday, March 21, 2023. These results are being presented by Dr. Michael Zile,

Professor of Cardiology at the Medical University of South Carolina (MUSC).

Highlights of the data presented by Dr. Zile include:

Dr. Zile's presentation concludes

that the "Totality of evidence indicates that BAT is a safe, effective and durable treatment for patients with heart failure with

reduced ejection fraction." The slides from Dr. Zile's featured presentation, as well as key slides that will be presented

as part of the CVRx-sponsored THT symposium, can be found at ir.cvrx.com.

are happy to see the significant long-term data that favored Barostim," added Nadim Yared, President and CEO of CVRx. "Interest

and adoption of the therapy continue to expand based on the previously-approved claims, and now we look forward to submitting this new

data to the FDA to pursue expanded labeling for Barostim. We are forever grateful to the patients, investigators, nurses, and research

staff involved in the study."

full results of BeAT-HF, including a number of additional analyses and endpoints, will be submitted by the executive steering committee

for publication in one or more peer-reviewed journals. CVRx anticipates that regulatory submission to the FDA for expanded labeling will

be made in the coming months.

CVRx is a commercial-stage medical device company focused on the developing,

manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases. Barostim is

the first medical technology approved by FDA that uses neuromodulation to improve the symptoms of patients with heart failure. Barostim

is an implantable device that delivers electrical pulses to baroreceptors located in the wall of the carotid artery. Baroreceptors activate

the body's baroreflex, which in turn triggers an autonomic response to the heart. The therapy is designed to restore balance to

the autonomic nervous system and thereby reduce the symptoms of heart failure. Barostim received the FDA Breakthrough Device designation

and is FDA-approved for use in heart failure patients in the U.S. It has also received the CE Mark for heart failure and resistant hypertension

in the European Economic Area. To learn more about Barostim, visit www.cvrx.com.

Forward-Looking Statements

This press release contains forward-looking statements within the

meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts are forward-looking

statements, including statements regarding our future financial performance, our anticipated growth strategies, anticipated trends in

our industry, our business prospects and our opportunities, including specifically those related to potential new indications, labelling

or marketing opportunities, our continued review and analysis of trial data and future business and financial impacts. In some cases,

you can identify forward-looking statements by terms such as "may," "will," "should," "expect,"

"plan," "anticipate," "could," "outlook," "guidance," "intend,"

"target," "project," "contemplate," "believe," "estimate," "predict,"

"potential" or "continue" or the negative of these terms or other similar expressions, although not all forward-looking

statements contain these words.

The forward-looking statements in this press release are only predictions

and are based largely on our current expectations and projections about future events and financial trends that we believe may affect

our business, financial condition, and results of operations. These forward-looking statements speak only as of the date of this press

release and are subject to a number of known and unknown risks, uncertainties and assumptions, including, uncertainties related to obtaining

regulatory approvals, further analysis and understanding of clinical trial data, physician and patient adoption, and other important

factors that could cause actual results, performance or achievements to differ materially from those projected in the forward-looking

statements that are found in "Part I, Item 1A. Risk Factors" in our Annual Report on Form 10-K for the year

ended December 31, 2022, as such factors may be updated from time to time in our other filings with the Securities and Exchange

Commission. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained

herein, whether as a result of any new information, future events, changed circumstances or otherwise.

Mark Klausner or Mike Vallie